Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions

Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02184052

Enrollment

121

Registered

2014-07-09

Start date

2003-07-31

Completion date

Unknown

Last updated

2014-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Rheumatoid

Brief summary

Study to determine the safety and efficacy of Mobic® ampoules in the initiation of treatment of painful exacerbations of osteoarthritis, rheumatoid arthritis and other similar painful inflammatory conditions.

Interventions

DRUGMeloxicam

7.5 mg or 15 mg

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Painful acute exacerbations of inflammatory rheumatism (rheumatoid arthritis and ankylosing spondylitis), painful acute exacerbations of osteoarthritis and other similar conditions requiring acute treatment with an anti-inflammatory drug

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
Overall assessment of degree of pain on a 3-point scale	up to 3 days

Secondary

Measure	Time frame
Number of patients with adverse events	up to 3 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026